Syndax Pharmaceuticals Q1 2026 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Source: seekingalpha
- Strong Sales Performance: Syndax Pharmaceuticals achieved over $100 million in combined sales of Revuforj and Niktimvo in Q1 2026, demonstrating robust demand for both medicines and advancing the company towards profitability.
- Revuforj Revenue Growth: Revuforj net revenue reached $49 million, significantly increasing the estimate of KMT2A patients able to receive potentially curative stem cell transplants to nearly 50%, up from the previous estimate of 33%, indicating improved treatment efficacy.
- Stable Niktimvo Performance: Niktimvo delivered $55 million in net revenue in Q1, reflecting consistent new patient starts despite natural attrition, suggesting strong ongoing market demand.
- Sufficient Funding: As of March 31, 2026, the company reported $352.1 million in cash, cash equivalents, and marketable securities, ensuring the ability to continue investing in its R&D and commercial priorities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNDX
Wall Street analysts forecast SNDX stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.750
Low
27.00
Averages
39.11
High
56.00
Current: 19.750
Low
27.00
Averages
39.11
High
56.00
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Syndax's Revuforj Showcases New Data at ASCO Meeting
- Clinical Trial Results: At the upcoming ASCO Annual Meeting, Syndax will present clinical data from 21 acute leukemia patients treated with Revuforj, demonstrating favorable overall survival and relapse rates, which could enhance the drug's acceptance in post-transplant maintenance therapy.
- Pharmacokinetic Features: The pharmacokinetic data of Revuforj will be highlighted, emphasizing its unique ability to be administered with commonly prescribed gastric acid reducers without compromising efficacy, which may improve patient adherence and strengthen market competitiveness.
- New Trial Designs: Syndax will showcase key trial designs for Revuforj in combination with varying intensities of chemotherapy, particularly for newly diagnosed patients with NPM1 mutations or KMT2A rearrangements, providing crucial evidence for future treatment protocols that could redefine standard care.
- Scientific Leadership: Syndax's strong presence at ASCO not only underscores its scientific leadership in menin inhibition but also reflects its deep commitment to advancing cancer care, likely attracting increased investor interest in its research pipeline.
See More
Revumenib Shows Promising Results in Acute Leukemia Treatment
- Clinical Data Highlights: Syndax Pharmaceuticals presented 12 abstracts on Revuforj (revumenib) at the EHA 2026 Congress, demonstrating strong clinical activity across acute leukemia subtypes, particularly KMT2Ar, NPM1m, and NUP98r, potentially transforming treatment paradigms.
- Efficacy and Tolerability: New real-world data show that revumenib, both as monotherapy and in combination, exhibits favorable tolerability and significant efficacy in acute leukemia patients, particularly in the post-transplant setting, supporting physician decision-making and enhancing confidence in ongoing clinical trials.
- Frontline and Relapse Data: The combination of revumenib with intensive chemotherapy shows up to 50% MRD negativity rates and significantly improved transplant success rates in newly diagnosed acute myeloid leukemia patients, indicating its potential in clinical applications.
- Scientific Leadership: Nick Botwood, Chief Medical Officer of Syndax, stated that these data underscore the company's scientific leadership in menin inhibition, with expectations to provide new treatment options for over 50% of acute myeloid leukemia patients.
See More
Syndax Pharmaceuticals Q1 2026 Earnings Call Highlights
- Strong Sales Performance: Syndax Pharmaceuticals achieved over $100 million in combined sales of Revuforj and Niktimvo in Q1 2026, demonstrating robust demand for both medicines and advancing the company towards profitability.
- Revuforj Revenue Growth: Revuforj net revenue reached $49 million, significantly increasing the estimate of KMT2A patients able to receive potentially curative stem cell transplants to nearly 50%, up from the previous estimate of 33%, indicating improved treatment efficacy.
- Stable Niktimvo Performance: Niktimvo delivered $55 million in net revenue in Q1, reflecting consistent new patient starts despite natural attrition, suggesting strong ongoing market demand.
- Sufficient Funding: As of March 31, 2026, the company reported $352.1 million in cash, cash equivalents, and marketable securities, ensuring the ability to continue investing in its R&D and commercial priorities.
See More
Syndax Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Highlights: Syndax Pharmaceuticals reported a Q1 GAAP EPS of -$0.48, beating expectations by $0.13, indicating an improving trend in the company's profitability.
- Revenue Surge: The company achieved revenue of $64.9 million in Q1, representing a remarkable year-over-year growth of 223.9%, although it fell short of expectations, reflecting strong market demand for its products.
- Expense Forecast: For the full year 2026, total research and development plus selling, general, and administrative expenses are expected to be approximately $400 million, excluding an estimated $50 million in non-cash stock compensation, highlighting the company's ongoing investment in business expansion.
- Market Outlook: Despite missing revenue expectations, Syndax's robust growth momentum and upcoming drug launches may attract investor interest and enhance market confidence.
See More
Syndax Pharmaceuticals to Report Q1 2026 Financial Results
- Earnings Release Schedule: Syndax Pharmaceuticals is set to announce its Q1 2026 financial results on April 30, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Details: Management will host a conference call and live audio webcast at 4:30 p.m. ET on the same day, providing investors with direct access to company updates and enhancing transparency.
- Replay Availability: For those unable to attend the live session, a replay will be accessible approximately 24 hours post-call and will remain available for 90 days, ensuring widespread dissemination of critical information.
- Pipeline Highlights: Syndax's pipeline features FDA-approved cancer therapies like Revuforj® and Niktimvo™, showcasing the company's ongoing commitment and potential in cancer treatment, which may attract increased investor interest.
See More
DAFNA Capital Reduces Stake in Syndax Pharmaceuticals
- Share Reduction Details: DAFNA Capital reported in its February 17, 2026 SEC filing that it sold 222,847 shares of Syndax Pharmaceuticals in Q4, with an estimated transaction value of $3.89 million, reflecting a cautious outlook on the company's future performance.
- Ownership Percentage Change: Following the sale, DAFNA's stake in Syndax decreased to 1.36% from 1.90% in the previous quarter, indicating a strategic adjustment in its investment portfolio.
- Market Performance Comparison: As of last Friday, Syndax's stock price stood at $24.23, marking a 72% increase over the past year, significantly outperforming the S&P 500's 15% rise during the same period, highlighting its strong position in the biopharmaceutical sector.
- Company Growth Prospects: Syndax focuses on developing oncology therapies, and despite facing high operating costs and ongoing losses, its $172 million in 2025 sales and rapidly scaling commercial products demonstrate its potential in transitioning from clinical to commercial-stage biotech.
See More
Syndax's Revuforj Showcases New Data at ASCO Meeting
- Clinical Trial Results: At the upcoming ASCO Annual Meeting, Syndax will present clinical data from 21 acute leukemia patients treated with Revuforj, demonstrating favorable overall survival and relapse rates, which could enhance the drug's acceptance in post-transplant maintenance therapy.
- Pharmacokinetic Features: The pharmacokinetic data of Revuforj will be highlighted, emphasizing its unique ability to be administered with commonly prescribed gastric acid reducers without compromising efficacy, which may improve patient adherence and strengthen market competitiveness.
- New Trial Designs: Syndax will showcase key trial designs for Revuforj in combination with varying intensities of chemotherapy, particularly for newly diagnosed patients with NPM1 mutations or KMT2A rearrangements, providing crucial evidence for future treatment protocols that could redefine standard care.
- Scientific Leadership: Syndax's strong presence at ASCO not only underscores its scientific leadership in menin inhibition but also reflects its deep commitment to advancing cancer care, likely attracting increased investor interest in its research pipeline.
See More
Revumenib Shows Promising Results in Acute Leukemia Treatment
- Clinical Data Highlights: Syndax Pharmaceuticals presented 12 abstracts on Revuforj (revumenib) at the EHA 2026 Congress, demonstrating strong clinical activity across acute leukemia subtypes, particularly KMT2Ar, NPM1m, and NUP98r, potentially transforming treatment paradigms.
- Efficacy and Tolerability: New real-world data show that revumenib, both as monotherapy and in combination, exhibits favorable tolerability and significant efficacy in acute leukemia patients, particularly in the post-transplant setting, supporting physician decision-making and enhancing confidence in ongoing clinical trials.
- Frontline and Relapse Data: The combination of revumenib with intensive chemotherapy shows up to 50% MRD negativity rates and significantly improved transplant success rates in newly diagnosed acute myeloid leukemia patients, indicating its potential in clinical applications.
- Scientific Leadership: Nick Botwood, Chief Medical Officer of Syndax, stated that these data underscore the company's scientific leadership in menin inhibition, with expectations to provide new treatment options for over 50% of acute myeloid leukemia patients.
See More
Syndax Pharmaceuticals Q1 2026 Earnings Call Highlights
- Strong Sales Performance: Syndax Pharmaceuticals achieved over $100 million in combined sales of Revuforj and Niktimvo in Q1 2026, demonstrating robust demand for both medicines and advancing the company towards profitability.
- Revuforj Revenue Growth: Revuforj net revenue reached $49 million, significantly increasing the estimate of KMT2A patients able to receive potentially curative stem cell transplants to nearly 50%, up from the previous estimate of 33%, indicating improved treatment efficacy.
- Stable Niktimvo Performance: Niktimvo delivered $55 million in net revenue in Q1, reflecting consistent new patient starts despite natural attrition, suggesting strong ongoing market demand.
- Sufficient Funding: As of March 31, 2026, the company reported $352.1 million in cash, cash equivalents, and marketable securities, ensuring the ability to continue investing in its R&D and commercial priorities.
See More
Syndax Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Highlights: Syndax Pharmaceuticals reported a Q1 GAAP EPS of -$0.48, beating expectations by $0.13, indicating an improving trend in the company's profitability.
- Revenue Surge: The company achieved revenue of $64.9 million in Q1, representing a remarkable year-over-year growth of 223.9%, although it fell short of expectations, reflecting strong market demand for its products.
- Expense Forecast: For the full year 2026, total research and development plus selling, general, and administrative expenses are expected to be approximately $400 million, excluding an estimated $50 million in non-cash stock compensation, highlighting the company's ongoing investment in business expansion.
- Market Outlook: Despite missing revenue expectations, Syndax's robust growth momentum and upcoming drug launches may attract investor interest and enhance market confidence.
See More
Syndax Pharmaceuticals to Report Q1 2026 Financial Results
- Earnings Release Schedule: Syndax Pharmaceuticals is set to announce its Q1 2026 financial results on April 30, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Details: Management will host a conference call and live audio webcast at 4:30 p.m. ET on the same day, providing investors with direct access to company updates and enhancing transparency.
- Replay Availability: For those unable to attend the live session, a replay will be accessible approximately 24 hours post-call and will remain available for 90 days, ensuring widespread dissemination of critical information.
- Pipeline Highlights: Syndax's pipeline features FDA-approved cancer therapies like Revuforj® and Niktimvo™, showcasing the company's ongoing commitment and potential in cancer treatment, which may attract increased investor interest.
See More
DAFNA Capital Reduces Stake in Syndax Pharmaceuticals
- Share Reduction Details: DAFNA Capital reported in its February 17, 2026 SEC filing that it sold 222,847 shares of Syndax Pharmaceuticals in Q4, with an estimated transaction value of $3.89 million, reflecting a cautious outlook on the company's future performance.
- Ownership Percentage Change: Following the sale, DAFNA's stake in Syndax decreased to 1.36% from 1.90% in the previous quarter, indicating a strategic adjustment in its investment portfolio.
- Market Performance Comparison: As of last Friday, Syndax's stock price stood at $24.23, marking a 72% increase over the past year, significantly outperforming the S&P 500's 15% rise during the same period, highlighting its strong position in the biopharmaceutical sector.
- Company Growth Prospects: Syndax focuses on developing oncology therapies, and despite facing high operating costs and ongoing losses, its $172 million in 2025 sales and rapidly scaling commercial products demonstrate its potential in transitioning from clinical to commercial-stage biotech.
See More
